Skip to main content

Table 1 Primers used for construction of the rNDV expressing IBV S protein vaccine candidates

From: Development of a recombinant Newcastle disease virus-vectored vaccine for infectious bronchitis virus variant strains circulating in Egypt

Primer number Primer name Primer sequence
1 COS-2167F (SmaI)a ACTCTGAAAGACCTGATCTGCG
2 COS-(YA) Rev AGTTGTGGCGTAGGAGCTTTTCb
3 COS-(YA) Fwd AGCTCCTACGCCACAACTTTTGc
4 COS-R (StuI-PmeI-Fct12) AGGCCTGTTTAAACTCACATTTTAGTGGTTGCCCTCATTTGATCCAAAGTGTTCACTGATTTCTTGGGTCTGTACd
5 COSΔct-R (StuI-PmeI-Fct12) AGGCCTGTTTAAACTCACATTTTAGTGGTTGCCCTCATTTGATCCAAAGTGTTAAAGAAGATCCACCCCAGGATCe
  1. aThe primer sequence is just upstream to the naturally present SmaI sequence at the nt position 2167 of the codon-optimized S gene sequence.
  2. bThe sequence “GGC” in bold indicates the reverse complementary mutagenic sequence of alanine residue at nt position 3433–3435 of the codon-optimized S gene sequence.
  3. cThe sequence “GCC” in bold indicates the mutagenic sequence of alanine residue at nt position 3433–3435 of the codon-optimized S gene sequence.
  4. dUnderlined sequence indicates StuI, italicized sequence in indicates PmeI, sequence in regular font indicates nt coding for optimized last 12 aa of NDV F protein, sequence in bold indicates the N terminus of IBV S specific sequence.
  5. eUnderlined sequence indicates StuI, italicized sequence indicates PmeI, sequence in regular font indicates nt coding for optimized last 12 aa of NDV F protein, sequence in bold indicates the N terminus of the transmembrane domain of IBV S specific sequence.